Robert B Fick, Jr MD; and Paul C St...

Robert B Fick, Jr MD; and Paul C Stillwell, MD FCCP

Cystic fibrosis is a systemic disorder transmitted from autosomal recessive genetics which is still characterized as the mostly common fatal genetic disease in whites. Approximately 5 percent of the US white population are carriers of the CF gene Carriers of the CF mutation do not manifest symptoms, a heterozygote advantage has not been demonstrated, and there is at not away no carrier test that can be applied to the general population. The basic biochemical abnormality in CF is not known, although rapid progres is being made toward that last Molecular biologists using recombinant DNA techniques have located the CF gene in succession a small portion of the in extent arm of chromosome 7, providing a major stair toward isolating the gene itself and finally understanding the biochemical pathways involved in the clinical manifestations of CF

All fields of medicine may be touched on this disease, and it is possible for the astute physician to find adult patients with CF while evaluating chronic sinusitis, asthma, pancreatic insufficiency, sprue-like symptoms, azoospermia, or cirrhosis and portal hypertension. Similarly, there is great variability in the clinical course of this disease, and deterioration does not take place at the same rate in all patients. Although CF is a systemic disorder, it is the pulmonary disease, renewed pulmonary bacterial infections superimposed forward chronic colonization of the airways and resultant inflammation leading to destructive disease of the airways (bronchiectasis), which causes chiefly of the morbidity. Ninety percent of CF patients die of respiratory failure.

Despite the promise that molecular biology shut ups for the ultimate therapy for CF standard care for pulmonary disease fit to CF today remains based in succession prompt initiation of effective treatment of the disease of the airways. In 1988 widespread diagnostic and therapeutic programs have made possible an increased median survival to almost 27 years in CF center In the paragraphs that tread on the heels of we will present a limited summary of the two new and old therapies that remain controversial. The sense of such a, necessarily, circumscribed review is to highlight therapeutic modalities of promise and to show up common treatments based on inadequate data, in an attempt to provide debate between colleagues, to stimulate clinical trials, and to hint directions for future clinical investigation.

THE CF PULMONARY LESION

The lung in CF are morphologically normal at birth, and the attack of pulmonary pathology may arise anytime after birth, with varying severity of the resulting respiratory signs and symptoms. by dint of the time patients with CF insert adulthood, only 2 percent lack evidence of pulmonary disease at history, by chest radiographic examination, and on pulmonary function tests. newly come morphometric work performed on lung from patients with CF obtained at autopsy indicate that the airway disease and pulmonary remodeling are irregularly distributed and that the upper lobe portions are disproportionately involved.[1] Careful light-microscopic and electron microscopic studies have failed to identify a single lesion specific for CF In contradistinction to the usual pseudomonas pneumonia, the lesion in CF is largely confined to the airway, with destruction of the wall leading to bronchiolitis and eventually bronchiectasis. As the airway disease becomes established, patchy areas of parenchymal involvement (bronchopneumonia) may become more apparent (Fig 1)

Many adults will have a lengthy history of respiratory infections which started in childhood. Pulmonary disease owing to CF may present acutely with staphylococcal pneumonia or insidiously with persistent cough following an apparent viral upper respiratory infection. The acquisition of mucoid Pseudomonas aeruginosa in respiratory secretions marks the beginning of a inert decline in pulmonary function. Respiratory infection[unkeyable] in CF run afters a smoldering course punctuated on acute exacerbations (in part caused by the agency of viral agents) superimposed upon a baseline of chronic productive cough and bacterial colonization, in the greatest degree commonly caused by mucoid P aeruginosa. Curiously, during these airway infections, temperature elevations are singular routine blood cell counts are generally not helpful, and positive agricultures of blood are practically unknown. Greater than 90 percent of the deaths owing to CF occur during single of these pulmonary infections, and it is a rare incident that pseudomonas is eradicated from the sputum regardless of the antibiotic regimen selected

Although P aeruginosa is the greatest in quantity common bacterial isolate obtained from the airways of adult patients with CF freshly new multiresistant organisms have emerg single in kind nonaeruginosa strain, P cepacia, has been associated with increased morbidity and premature death in a subgroup of patients with CF During acute flare-ups of pulmonary symptoms, 5 to 15 percent of the bacterial strains isolated from samples of sputum may be nonaeruginosa pseudomonas.